title: [mRNA quantification. The next challenge in routine diagnostics].
abstract: The application of predictive biomarkers results in an increase in the response rates and overall survival of cancer patients. This had been shown impressively for the detection of mutations in the proto-oncogenes KRAS and EGFR for the application of anti-EGFR targeted therapies in metastatic colorectal carcinomas and non-small-cell lung cancer, respectively. This mutation detection is of a qualitative nature. In addition, predictive biomarkers are known for the use of the commonly administered chemotherapeutics 5-fluorouracil, platinum-containing complexes, and Irinotecan, which are normally identical to the targets of the therapeutic compounds. The determination of these predictive biomarkers also results in an increase in response rates and overall survival. However, this detection is done via the quantitative determination of mRNA expression levels, implying greater efforts in detection, knowledge of cut-off levels, and higher requirements for nationwide establishment.
authors.affiliation: Pathologisches Institut, Ludwig-Maximilians-Universität München, Thalkirchner Str. 36, 80337 München. andreas.jung@lmu.de
authors.forename: A
authors.initials: A
authors.lastname: Jung
authors.forename: S
authors.initials: S
authors.lastname: Jaitner
authors.forename: A J
authors.initials: AJ
authors.lastname: Schäffauer
authors.forename: T
authors.initials: T
authors.lastname: Kirchner
mesh_terms: D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000473:pathology; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000473:pathology; D016503:Drug Delivery Systems; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000473:pathology; D025202:Molecular Diagnostic Techniques; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D011237:Predictive Value of Tests; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics*; D015996:Survival Rate; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; D012333:RNA, Messenger; D000077150:Oxaliplatin; D000077146:Irinotecan; D013940:Thymidylate Synthase; D005472:Fluorouracil; D002166:Camptothecin
references.citation: Int J Cancer. 2006 Nov 15;119(10):2435-42
references.pmid: 16894565
references.citation: J Clin Oncol. 2001 Dec 1;19(23):4298-304
references.pmid: 11731512
references.citation: Z Gastroenterol. 2008 Aug;46(8):799-840
references.pmid: 18759205
references.citation: Biotechniques. 2004 Jun;36(6):1030-7
references.pmid: 15211754
references.citation: Am J Pharmacogenomics. 2003;3(2):73-88
references.pmid: 12749725
references.citation: Clin Cancer Res. 2000 Apr;6(4):1322-7
references.pmid: 10778957
references.citation: Nat Rev Cancer. 2009 Jul;9(7):489-99
references.pmid: 19536109
references.citation: Science. 2008 Sep 26;321(5897):1801-6
references.pmid: 18772397
references.citation: J Clin Oncol. 1997 Oct;15(10):3223-9
references.pmid: 9336359
references.citation: Clin Pharmacol Ther. 2001 Mar;69(3):89-95
references.pmid: 11240971
references.citation: Pathologe. 2010 Feb;31(1):16-21
references.pmid: 19957085
references.citation: Clin Cancer Res. 1998 Oct;4(10):2371-6
references.pmid: 9796967
references.citation: Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205
references.pmid: 12084461
references.citation: Am J Surg. 1968 Feb;115(2):140-7
references.pmid: 5635578
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Nature. 2001 May 17;411(6835):366-74
references.pmid: 11357144
references.citation: Scand J Clin Lab Invest Suppl. 2010;242:63-5
references.pmid: 20515280
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4131-7
references.pmid: 18757326